Tislelizumab

Tislelizumab
	Fab fragment of tislelizumab (green) binding the extracellular domain of PD-1 (pale pink). From PDB entry 7BXA
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	PD-1
Clinical data
Trade names	Tevimbra
Other names	BGB-A317, tislelizumab-jsgr
AHFS/Drugs.com	Monograph
MedlinePlus	a624026
License data	US DailyMed: Tislelizumab;
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
Drug class	Antineoplastic agent
ATC code	L01FF09 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	1858168-59-8;
DrugBank	DB14922;
ChemSpider	none;
UNII	0KVO411B3N;
KEGG	D11487;

Tislelizumab, sold under the brand name Tevimbra among others, is an anti-cancer medication used for the treatment of various forms of cancer. It is a humanized monoclonal antibody directed against programmed death receptor-1. It is being developed by BeiGene.

Tislelizumab was approved for medical use in China in December 2019, in the European Union in September 2023, in the United States in March 2024, and in Australia in May 2024.